MAP Pharmaceuticals to Host Conference Call on Friday, December 19 to Discuss Worldwide Collaboration with AstraZeneca for UDB

Saturday, December 20, 2008 General News J E 4
MOUNTAIN VIEW, Calif., Dec. 19 MAPPharmaceuticals, Inc. (Nasdaq: MAPP) will host a conference call at 8:45 a.m.ET / 5:45 a.m. PT, Friday, December 19, to update shareholders on theworldwide collaboration with AstraZeneca for Unit Dose Budesonide (UDB)announced today.

You may join the call via telephone at 888-670-2248 (domestic) or 913-312-0980 (international). Access to the live webcast will be available via theInvestor Relations section of the Company's Website at Areplay will also be available within 24 hours for at least seven daysfollowing the conference call.

About MAP Pharmaceuticals

MAP Pharmaceuticals, Inc. develops and plans to commercialize newtherapies for children and adults who suffer from chronic conditions that itbelieves are not adequately treated by currently available medicines. Thecompany applies its proprietary inhalation technologies to enhance thetherapeutic benefits and commercial attractiveness of proven drugs whileminimizing risk by capitalizing on their known safety, efficacy andcommercialization history. MAP Pharmaceuticals has two drug candidates inPhase 3 clinical trials. Unit Dose Budesonide is being developed for thepotential treatment of pediatric asthma, and MAP0004 is being developed forthe potential treatment of migraine. MAP Pharmaceuticals' pipeline alsoincludes a drug candidate in early clinical development for the treatment ofasthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at

SOURCE MAP Pharmaceuticals


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
VivoMetrics Partners With Continua Health Alliance...
AstraZeneca and MAP Pharmaceuticals Announce World...